Using protein patterns to predict how cancer drugs will work
Official title: Proteomic signatures to predict drug response in cancer
Funded at University of Washington · NIH-11076345 · Data updated 2026-11-12
This study is looking at how certain proteins in liver cancer cells can help doctors figure out which cancer drugs will work best for individual patients, so they can get more personalized treatment based on their specific tumor.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | April 17, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $181,741 |
| NIH project number | 5R21CA288806-02 |
| Project ID | NIH-11076345 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with liver cancer who are considering treatment options.
✕Less likely to help
Patients with cancers other than liver cancer may not benefit from this specific research.
What this research studies
This research investigates how specific protein activity in liver cancer cells can predict the effectiveness of various cancer drugs. By analyzing samples from normal liver tissue and liver cancer cell lines, the team aims to refine a predictive model called the KI-Predictor. This model will be tested using actual liver cancer samples from patients to see how well it can forecast drug responses in a lab setting. The goal is to improve personalized treatment options for patients based on their unique tumor characteristics.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized cancer treatments for patients.
How similar studies have gone: Other research has shown promising results using similar proteomic approaches to predict drug responses in cancer treatment.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Ong, Shao-En — University of Washington
- Study coordinator: Ong, Shao-En
Related research
Other NIH-funded projects on the same topics.
-
Making genetic testing more accessible to the public
This study is all about making it easier for people at risk of certain cancers, like breast, ovarian, and colon cancers, to get genetic testing, so we can find out what helps them access these important services and understand how they can benefit from them.
-
Breast cancer diagnosis in low-resource settings using millifluidics and fast digital imaging in Ghana
A new project will test a fast, low-cost way to diagnose breast cancer at the point of care in Ghana using small-batch fluidics and direct digital imaging.
-
Binaural Hearing and Speech in Noise in Children
This project explores how children hear speech in noisy classrooms using how the two ears work together to see if binaural processing differences explain why some kids struggle more than others.
-
Neural circuits that control pain aversion in the brain
Researchers are exploring how a specific brain area helps people feel and avoid pain, with potential to lead to better pain treatments.
-
United World Antiviral Research Network (UWARN)
A collaborative, international effort is testing new virus surveillance and evolution ideas to help people living with HIV and communities in LMICs stay safer from current and emerging viruses.
-
HF endotypes in heart failure using ethical multi-modal AI and molecular data
A patient-friendly project that uses advanced AI and multiple kinds of health data to identify distinct heart failure subtypes that could guide personalized care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.